Compare Adaptive Biotechnologies Corp (ADPT) vs GXO Logistics Inc (GXO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs GXO Logistics Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while GXO Logistics Inc trades at $50.09 (market cap $5.89B). The key difference: GXO Logistics Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | GXO | |
|---|---|---|
Market Cap | $3.33B | $5.89B |
Sector | Health | Industrials |
52-Week High | $22.37 | $65.59 |
52-Week Low | $10.24 | $45.52 |
Enterprise Value | $3.19B | $11.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GXO trades at $51.16, down 1.52% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and a record sales pipeline of $2.7 billion highlight operational momentum. The company secured multiple long-term partnerships in Europe, reinforcing its contract logistics leadership.
Outlook remains positive with a consensus price target of $69.33, implying 35% upside. Risks include Amazon's market entry and retail sector exposure. Revenue growth and margin expansion in 2026 forecasts support a bullish case, though competition and macro pressures warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
